MX390651B - Compuestos para el tratamiento de trastornos hipoproliferativos - Google Patents

Compuestos para el tratamiento de trastornos hipoproliferativos

Info

Publication number
MX390651B
MX390651B MX2018005158A MX2018005158A MX390651B MX 390651 B MX390651 B MX 390651B MX 2018005158 A MX2018005158 A MX 2018005158A MX 2018005158 A MX2018005158 A MX 2018005158A MX 390651 B MX390651 B MX 390651B
Authority
MX
Mexico
Prior art keywords
treatment
compounds
hypoproliferative disorders
disorders
hypoproliferative
Prior art date
Application number
MX2018005158A
Other languages
English (en)
Other versions
MX2018005158A (es
Inventor
Johan Flygare
Lars Johansson
Thomas Lundbäck
Original Assignee
Apriligen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apriligen Inc filed Critical Apriligen Inc
Publication of MX2018005158A publication Critical patent/MX2018005158A/es
Publication of MX390651B publication Critical patent/MX390651B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de inhibidores de CDK8 y/o CDK19 en el tratamiento de ribosomopatias así como afecciones caracterizadas por una menor cantidad de células madre hematopoyeticas y/o células progenitoras y trastornos anabólicos óseos.
MX2018005158A 2015-11-03 2016-11-03 Compuestos para el tratamiento de trastornos hipoproliferativos MX390651B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1551419 2015-11-03
PCT/EP2016/076550 WO2017076968A1 (en) 2015-11-03 2016-11-03 Compounds for treatment of hypoproliferative disorders

Publications (2)

Publication Number Publication Date
MX2018005158A MX2018005158A (es) 2019-05-16
MX390651B true MX390651B (es) 2025-03-21

Family

ID=57326350

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005158A MX390651B (es) 2015-11-03 2016-11-03 Compuestos para el tratamiento de trastornos hipoproliferativos

Country Status (10)

Country Link
US (1) US11471446B2 (es)
EP (1) EP3370720A1 (es)
JP (1) JP6977238B2 (es)
KR (1) KR20180073600A (es)
CN (1) CN108348509A (es)
AU (1) AU2016348659B2 (es)
BR (1) BR112018008931A8 (es)
IL (1) IL258593B (es)
MX (1) MX390651B (es)
WO (1) WO2017076968A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
JP7628252B2 (ja) * 2019-02-01 2025-02-10 ユニヴァーシティー オブ サウスカロライナ 二環式ピリジン組成物およびがんの治療にそれを使用する方法
US20220226343A1 (en) * 2019-05-21 2022-07-21 University Of South Carolina 3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
GB202208226D0 (en) * 2022-06-06 2022-07-20 Royal Veterinary College Method and treatment for osteoarthritis and diseases of chondrocyte hypertrophy
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
WO2024193640A1 (zh) * 2023-03-22 2024-09-26 上海齐鲁制药研究中心有限公司 Cdk抑制剂
WO2024219427A1 (ja) * 2023-04-18 2024-10-24 国立大学法人 京都大学 ２型自然リンパ球の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20041154A2 (en) * 2002-06-06 2005-06-30 Boehringer Ingelheim Pharmaceuticals Inc. SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBO
MXPA06011799A (es) 2004-04-12 2006-12-15 Sankyo Co Derivados de tienopiridina.
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
SG11201401343YA (en) * 2011-09-13 2014-08-28 Igor Roninson TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
US9321737B2 (en) 2012-02-02 2016-04-26 Senex Biotechnology Inc CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
WO2013138101A2 (en) 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
CA2880477A1 (en) 2012-08-23 2014-02-27 F. Hoffmann-La Roche Ag Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CA2885392A1 (en) 2012-12-10 2014-06-19 Zhanling CHENG Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194245A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
EP3122739B1 (en) * 2014-03-27 2019-01-16 Merck Patent GmbH Pyridyl piperidines

Also Published As

Publication number Publication date
US11471446B2 (en) 2022-10-18
IL258593A (en) 2018-06-28
WO2017076968A1 (en) 2017-05-11
JP2018532784A (ja) 2018-11-08
CN108348509A (zh) 2018-07-31
CA3002495A1 (en) 2017-05-11
BR112018008931A2 (pt) 2018-11-06
AU2016348659A1 (en) 2018-05-31
EP3370720A1 (en) 2018-09-12
MX2018005158A (es) 2019-05-16
AU2016348659B2 (en) 2022-07-28
IL258593B (en) 2021-04-29
KR20180073600A (ko) 2018-07-02
JP6977238B2 (ja) 2021-12-08
BR112018008931A8 (pt) 2019-02-26
US20190111034A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
MX390651B (es) Compuestos para el tratamiento de trastornos hipoproliferativos
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX381640B (es) Metodos y compuestos agonistas de gip.
ECSP14030779A (es) Inhibidores del nampt
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
UY37018A (es) Inhibidores bicíclicos de pad4
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
CL2015002897A1 (es) Inhibidores de bace1
CL2016002839A1 (es) Derivados de carboxamida
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.